Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00620568
NCT00620568
Terminated
Phase 1

An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder

Wyeth is now a wholly owned subsidiary of Pfizer0 sites32 target enrollmentFebruary 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy
InterventionsSLV-313 SR
DrugsSLV-313 SR

Overview

Phase
Phase 1
Intervention
SLV-313 SR
Conditions
Healthy
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
32
Primary Endpoint
Observe safety and tolerability
Status
Terminated
Last Updated
16 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSimilar Trials

Overview

Brief Summary

This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.

Registry
clinicaltrials.gov
Start Date
February 2008
End Date
March 2008
Last Updated
16 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • •Men, aged 18-50 years old
  • •Women, aged 18-50 years old

Exclusion Criteria

  • •Non-lactating women, aged 18-50 years old
  • •Non-pregnant women, aged 18-50 years old

Arms & Interventions

1

Intervention: SLV-313 SR

2

Intervention: SLV-313 SR

3

Intervention: SLV-313 SR

4

Intervention: SLV-313 SR

Outcomes

Primary Outcomes

Observe safety and tolerability

Time Frame: 25 days

Secondary Outcomes

  • PK and PD profile(25 days)

Similar Trials

Completed
Phase 1
Study of Multiple Doses of Danicopan in Healthy ParticipantsHealthy
NCT04889690Alexion Pharmaceuticals, Inc.45
Completed
Phase 1
A Study of Safety and Tolerability in Subjects With SchizophreniaSchizophrenia
NCT01354353Denovo Biopharma LLC75
Completed
Phase 1
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029Healthy
NCT00563810Wyeth is now a wholly owned subsidiary of Pfizer72
Completed
Phase 1
A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)Schizophrenia
NCT05406440Merck Sharp & Dohme LLC53
Completed
Phase 1
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)Alzheimer's Disease
NCT05227118Merck Sharp & Dohme LLC29